ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

Go back to ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
(NASDAQ: IBRX) Delayed: 7.22 -0.14 (1.9%)
Previous Close $7.36    52 Week High
Open $7.49    52 Week Low
Day High $7.55    P/E N/A 
Day Low $7.17    EPS
Volume 9,870,259